12:00 AM
Oct 15, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Status

Afrezza: Completed Phase III enrollment

MannKind completed enrollment in the double-blind, placebo-controlled, international Phase III Study 175 trial evaluating Afrezza using the inhaler MannKind used in Phase III testing in at least 328 Type II diabetics who are inadequately controlled on metformin with or without a second or...

Read the full 194 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >